2007 – AMPK Activator Licensing Deal Highlights Successful Collaboration between Boston-based Mercury Therapeutics and CreaGen Biosciences

May 3, 2007 by admin

BOSTON–(BUSINESS WIRE)–The recent licensing deal between Mercury Therapeutics and Debiopharm showcases the highly successful partnership between Mercury Therapeutics and CreaGen Biosciences, said CreaGen in a statement released today.

For the past three years, Mercury has partnered with CreaGen for medicinal chemistry-based outsourcing of their lead generation program seeking to develop small molecule activators of AMP activated protein kinase. Novel AMPK activators hold promise for the treatment of type 2 diabetes, cardiovascular disease, and cancer.

more…

admin



Subscribe


Sign up for CreaGen Inc newsletter to receive all the news.




Social networks



Twitter

#WeCare




Contact us




Send us an email

rrajur@creageninc.com



Subscribe


Sign up for Medicare newsletter to receive all the news offers and discounts from Medicare eye clinic.




Social networks



Twitter

#WeCare





© CreaGen Inc 2019. All rights reserved. Designed by Inqude



© CreaGen Inc 2019. All rights reserved. Designed by Inqude